icon-folder.gif   Conference Reports for NATAP  
 
  HepDART 2011
December 4, 2011 - December 8, 2011
Kauai, HI, USA
Back grey_arrow_rt.gif
 
 
 
No Significant Effect of the HCV Protease Inhibitor Telaprevir on Pharmacokinetics and Pharmacodynamics of Buprenorphine in HCV-negative Volunteers
 
 
  Reported by Jules Levin
HEP DART 2011, Koloa, Hawaii, USA, December 4-8, 2011
 
X Luo1, J Trevejo1, R van Heeswijk2, V Garg*1
1Vertex Pharmaceuticals Incorporated, Cambridge, MA, United States; 2Tibotec BVBA, Beerse, Belgium

HepDart1.gif

HepDart2.gif

HepDart3.gif

HepDart4.gif

HepDart5.gif

HepDart6.gif

HepDart7.gif

HepDart8.gif